Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's Disease

Axovant Sciences (AXON) PT Lowered to $25 at Cowen; Lewy Body Program Remains Focus

Cowen analyst Ritu Baral lowered his price target on Axovant Sciences (NASDAQ: AXON) to $25.00 (from $30.00) while maintaining an Outperform rating after the company reported the pivotal Ph3 MINDSET trial of intepirdine in Alzheimer's failed to meet its primary endpoint.

Baral notes... More

UPDATE: Piper Jaffray Downgrades Axovant Sciences (AXON) to Neutral

(Updated - September 26, 2017 11:02 AM EDT)

(updated to add analyst comment)

Piper Jaffray downgraded Axovant Sciences (NASDAQ: AXON) from Overweight to Neutral with a price target of $9.00 (from $32.00).

Analyst Charles Duncan says the pipeline needs to be rebuild... More

Oppenheimer Downgrades Axovant Sciences (AXON) to Perform

Oppenheimer downgraded Axovant Sciences (NASDAQ: AXON) from Outperform to Perform.

For an analyst ratings summary and ratings history on Axovant Sciences click here. For more ratings news on Axovant Sciences click here.

Shares of Axovant Sciences closed at $24.25 yesterday.

UPDATE: Axovant Sciences (AXON) PT Lowered to $3 at Chardan Capital Markets

(Updated - September 26, 2017 9:52 AM EDT)

(updated to add comments)

Chardan Capital Markets lowered its price target on Axovant Sciences (NASDAQ: AXON) to $3.00 (from $8.00) while maintaining a Sell rating after the company fails to demonstrate statistical significance on either co-primary endpoint (ADAS-Cog and ADCS-ADL) in the phase III MINDSET trial of intepirdine in mild-to-moderate... More

Baird Downgrades Axovant Sciences (AXON) to Neutral, $6 PT

Baird downgraded Axovant Sciences (NASDAQ: AXON) from Outperform to Neutral with a price target of $6.00 (from $29.00) after the failure of the Phase 3 MINDSET study in Alzheimer's.

Analyst Brian Skorney commented, " There may be a reasonable argument to allow thesis drift here, given the... More

Axovant Sciences (AXON) Sinks 70% as Trading Resumes

Axovant Sciences (NASDAQ: AXON) falls 70% to as trading resumes following trial failure.

Axovant Sciences (AXON) to Resume Trading at 7:30 AM ET

Axovant Sciences (NASDAQ: AXON) to Resume Trading at 7:30 AM ET